Apnimed sets sights on sleep apnoea pill approval following Phase III win
Following the success of its second Phase III trial on its investigative sleep apnoea medication, Apnimed has doubled down on …
Post
-
-
Novo Nordisk defeated in Wegovy patent dispute by Viatris
Danish weight-loss giant Novo Nordisk has lost a US patent to generics manufacturer Viatris. A federal district court in Delaware ruled …
-
Kling Bio and Sanofi link for antibodies and epitopes discovery
Kling Bio has entered a partnership and licence option agreement with Sanofi to discover neutralising antibodies and epitopes. The partnership will …
-
How ICH E6 (R3) is changing clinical trials
The latest ICH E6 (R3) guidelines could transform how clinical studies are built and operated. The updated ICH E6 (R3) guidelines …
-
Exploring AI-powered cell simulations and the launch of the world’s first virtual lab
Artificial intelligence and machine learning (AI/ML) are fundamentally changing the world of drug discovery, enabling researchers to identify the potential …
-
Janssen’s Darzalex new indication gains EC approval for SMM
The European Commission (EC) has approved the Johnson & Johnson company Janssen-Cilag International’s new indication for Darzalex Faspro (daratumumab) subcutaneous …
-
UK enacts law to decentralise manufacture of personalised treatments
The UK Government has passed legislation to decentralise the manufacture of personalised medicines, allowing them to be prepared in facilities …
-
AstraZeneca announces $50bn US investment plans by 2030
AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing, and research and development (R&D). The investment …
-
Sanofi to acquire Vicebio’s share capital for $1.15bn upfront
Sanofi has signed an agreement to acquire UK-based biotechnology company Vicebio’s share capital for $1.15bn upfront, to expand its vaccine …
-
J&J seeks FDA approval for icotrokinra to treat psoriasis
Johnson & Johnson (J&J) has submitted a new drug application (NDA) seeking approval from the US Food and Drug Administration …
-
Sarepta halts Elevidys shipments following FDA pressure
Sarepta Therapeutics has yielded to the US Food and Drug Administration (FDA), agreeing to suspend shipments of Elevidys (delandistrogene moxeparvovec) …
-
Biogen to invest further $2bn in North Carolina’s Research Triangle Park
Biogen has announced plans to invest an additional $2bn in Research Triangle Park (RTP) in the US state of North …
-
Quantum leap or quantum hype: the role of quantum computing in protein modelling
The rapid advancement of AI-powered tools, such as RoseTTAFold and AlphaFold, has revolutionised protein structure prediction, creating exciting opportunities across …
-
Life sciences VC Omega Funds closes $647m funding round
Life sciences venture capital (VC) company Omega Funds has closed its eighth fund, with capital commitments totalling $647m. As with its …
-
Sarepta refuses to pull gene therapy despite FDA request
Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the US Food and …
